Video Experimental Relacionado
Updated: Jan 8, 2026
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
6.0K
Caracterización de Nuevos Péptidos Inhibidores de la Enzima Convertidora de Angiotensina
Camila Innocente-Alves1,2, Sara Luísa Sulzbach1, Emerson Gonçalves Moreira3
1Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, Brazil.
ACS medicinal chemistry letters
|December 17, 2025
Resumen
Dos nuevos péptidos bioactivos muestran potencial para controlar la hipertensión al inhibir la enzima convertidora de angiotensina (ECA). Estos péptidos pueden conducir a nuevos fármacos antihipertensivos con menos efectos secundarios.
Área de la Ciencia:
- Bioquímica
- Farmacología
- Investigación Cardiovascular
Sus antecedentes:
- La hipertensión es una de las principales causas de mortalidad a nivel mundial, a menudo mal controlada debido a los efectos adversos de los tratamientos actuales.
- El sistema renina-angiotensina (SRA) y su enzima clave, la enzima convertidora de angiotensina (ECA), son objetivos críticos para las terapias antihipertensivas.
- Los péptidos bioactivos son reconocidos por sus diversas actividades biológicas, incluidas las posibles propiedades antihipertensivas.
Objetivo del estudio:
- Identificar y caracterizar nuevos péptidos bioactivos con actividad inhibidora de la enzima convertidora de angiotensina (ECA).
- Evaluar el potencial de estos péptidos como base para el desarrollo de nuevos fármacos antihipertensivos.
Principales métodos:
- Síntesis y caracterización de dos nuevos péptidos: MSFLEHFLELK (PepDB_AHP1) y VWTNCYHLYPAH (PepDB_AHP4).
- Evaluación in vitro de la interacción del péptido con el sitio activo de la enzima convertidora de angiotensina (ECA).
- Determinación de las concentraciones inhibitorias (IC50) para los péptidos identificados contra la ECA.
Principales resultados:
- Ambos péptidos novedosos, PepDB_AHP1 y PepDB_AHP4, demostraron interacción con residuos clave en el sitio activo de la ECA.
- Los valores de IC50 para PepDB_AHP1 y PepDB_AHP4 se determinaron en 331,2 μM y 88,63 μM, respectivamente.
- Estos hallazgos indican un potencial significativo de inhibición de la ECA para ambos péptidos.
Conclusiones:
- Los nuevos péptidos PepDB_AHP1 y PepDB_AHP4 exhiben una prometedora actividad inhibidora de la enzima convertidora de angiotensina (ECA).
- Estos péptidos pueden servir como modelos valiosos para el desarrollo futuro de inhibidores de la ECA optimizados.
- La investigación adicional sobre estos péptidos podría conducir a nuevas estrategias terapéuticas para el manejo de la hipertensión.
Videos de Conceptos Relacionados
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424